Sorafenib in BAC or Never-Smokers With Lung Adenocarcinoma

Swedish Medical Center

Status and phase: Completed; Phase 2

Conditions: Lung Cancer

Treatments: Drug: sorafenib

Study type: Interventional

Funder types: Other; Industry

Identifiers

NCT00456716

CRC 0639

Details and patient eligibility

About

Open label study of sorafenib

Full description

Open label study using oral sorafenib 800 mg daily in any stage III-IV BAC lung cancer and Stage III-IV adenocarcinoma of the lung in nonsmokers (less than < 100 cigarettes lifetime).

Enrollment: 5 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Age > 18
• Life expectancy > 12 weeks
• Biopsy-proven BAC or adenocarcinoma
• Willing to provide smoking status
• Selected IIIB or stage IV cancer that is incompletely resected or unresectable

Exclusion criteria

• O2 saturation < 88% on room air
• Pregnant or nursing women
• Surgery or radiation therapy within 4 weeks of starting study
• Major heart condition within 6 months of starting therapy
• Certain concomitant medications prohibited

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)